Pavla Hujová1,2, Přemysl Souček1,3, Lucie Grodecká1, Hana Grombiříková1,2, Barbora Ravčuková1, Pavel Kuklínek4, Roman Hakl2,4, Jiří Litzman2,4, Tomáš Freiberger5,6,7. 1. Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic. 2. Faculty of Medicine, Masaryk University, Brno, Czech Republic. 3. Central European Institute of Technology, Masaryk University, Brno, Czech Republic. 4. Department of Allergology and Clinical Immunology, St. Anne's University Hospital in Brno, Brno, Czech Republic. 5. Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic. tomas.freiberger@cktch.cz. 6. Faculty of Medicine, Masaryk University, Brno, Czech Republic. tomas.freiberger@cktch.cz. 7. Central European Institute of Technology, Masaryk University, Brno, Czech Republic. tomas.freiberger@cktch.cz.
Abstract
PURPOSE: Hereditary angioedema (HAE) is a rare autosomal dominant life-threatening disease characterized by low levels of C1 inhibitor (type I HAE) or normal levels of ineffective C1 inhibitor (type II HAE), typically occurring as a consequence of a SERPING1 mutation. In some cases, a causal mutation remains undetected after using a standard molecular genetic analysis. RESULTS: Here we show a long methodological way to the final discovery of c.1029 + 384A > G, a novel deep intronic mutation in intron 6 which is responsible for HAE type I in a large family and has not been identified by a conventional diagnostic approach. This mutation results in de novo donor splice site creation and subsequent pseudoexon inclusion, the mechanism firstly described to occur in SERPING1 in this study. We additionally discovered that the proximal part of intron 6 is a region potentially prone to pseudoexon-activating mutations, since natural alternative exons and additional cryptic sites occur therein. Indeed, we confirmed the existence of at least two different alternative exons in this region not described previously. CONCLUSIONS: In conclusion, our results suggest that detecting aberrant transcripts, which are often low abundant because of nonsense-mediated decay, requires a modified methodological approach. We suggest SERPING1 intron 6 sequencing and/or tailored mRNA analysis to be routinely used in HAE patients with no mutation identified in the coding sequence.
PURPOSE: Hereditary angioedema (HAE) is a rare autosomal dominant life-threatening disease characterized by low levels of C1 inhibitor (type I HAE) or normal levels of ineffective C1 inhibitor (type II HAE), typically occurring as a consequence of a SERPING1 mutation. In some cases, a causal mutation remains undetected after using a standard molecular genetic analysis. RESULTS: Here we show a long methodological way to the final discovery of c.1029 + 384A > G, a novel deep intronic mutation in intron 6 which is responsible for HAE type I in a large family and has not been identified by a conventional diagnostic approach. This mutation results in de novo donor splice site creation and subsequent pseudoexon inclusion, the mechanism firstly described to occur in SERPING1 in this study. We additionally discovered that the proximal part of intron 6 is a region potentially prone to pseudoexon-activating mutations, since natural alternative exons and additional cryptic sites occur therein. Indeed, we confirmed the existence of at least two different alternative exons in this region not described previously. CONCLUSIONS: In conclusion, our results suggest that detecting aberrant transcripts, which are often low abundant because of nonsense-mediated decay, requires a modified methodological approach. We suggest SERPING1 intron 6 sequencing and/or tailored mRNA analysis to be routinely used in HAE patients with no mutation identified in the coding sequence.
Authors: Alessia David; Umasuthan Srirangalingam; Louise A Metherell; Bernard Khoo; Adrian J L Clark Journal: J Clin Endocrinol Metab Date: 2010-04-28 Impact factor: 5.958
Authors: Johanna Känsäkoski; Jarmo Jääskeläinen; Tiina Jääskeläinen; Johanna Tommiska; Lilli Saarinen; Rainer Lehtonen; Sampsa Hautaniemi; Mikko J Frilander; Jorma J Palvimo; Jorma Toppari; Taneli Raivio Journal: Sci Rep Date: 2016-09-09 Impact factor: 4.379
Authors: Kelly D Sullivan; Hannah C Lewis; Amanda A Hill; Ahwan Pandey; Leisa P Jackson; Joseph M Cabral; Keith P Smith; L Alexander Liggett; Eliana B Gomez; Matthew D Galbraith; James DeGregori; Joaquín M Espinosa Journal: Elife Date: 2016-07-29 Impact factor: 8.140
Authors: Alejandro Mendoza-Alvarez; Adrián Muñoz-Barrera; Luis Alberto Rubio-Rodríguez; Itahisa Marcelino-Rodriguez; Almudena Corrales; Antonio Iñigo-Campos; Ariel Callero; Eva Perez-Rodriguez; Jose Carlos Garcia-Robaina; Rafaela González-Montelongo; Jose Miguel Lorenzo-Salazar; Carlos Flores Journal: J Med Internet Res Date: 2020-10-09 Impact factor: 5.428
Authors: Christian Drouet; Alberto López-Lera; Arije Ghannam; Margarita López-Trascasa; Sven Cichon; Denise Ponard; Faidra Parsopoulou; Hana Grombirikova; Tomáš Freiberger; Matija Rijavec; Camila L Veronez; João Bosco Pesquero; Anastasios E Germenis Journal: Front Allergy Date: 2022-03-31